Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – N-c doai
Reexamination Certificate
2006-01-11
2010-12-07
Anderson, James D (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
N-c doai
C514S476000
Reexamination Certificate
active
07846968
ABSTRACT:
This invention is directed to methods for controlling the duration of the depolarization and repolarization of the cardiac ventricle and therefore the QT interval, in therapeutically useful ways in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II), or a pharmaceutically acceptable salt or ester thereof:wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5and R6are independently selected from the group consisting of hydrogen and C1-C4alkyl; wherein C1-C4alkyl is optionally substituted with phenyl, wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4alkyl, C1-C4alkoxy, amino, nitro and cyano.
REFERENCES:
patent: 3265728 (1966-08-01), Bossinger et al.
patent: 3313692 (1967-04-01), Bossinger et al.
patent: 5698588 (1997-12-01), Choi et al.
patent: 5854283 (1998-12-01), Choi et al.
patent: 6103759 (2000-08-01), Choi et al.
patent: 2002/0107283 (2002-08-01), Codd et al.
patent: WO 02/067923 (2002-09-01), None
Singh, “Quinidine-Like Activity of a New Central Depressant 2-hydroxy-2-phenylethyl Carbamate (Styramate)”, Archives Internationales De Pharmacodynamie Et De Therapie, 157(2):424-431 (1965) Coden: Aiptak; ISSN: 0003-9780, XP009065683.
Al-Muhammed, J., et al. “In-VivoStudies on Dexamethasone Sodium Phosphate Liposomes”, J. Microencapsulation (1996), vol. 13, No. 3, pp. 293-306.
Eyles, J., et al. “Oral Delivery and Fate of Poly(lactic acid) Microsphere-Encapsulated Interferon in Rats”, J. Pharm. Pharmacology (1997) vol. 49, pp. 669-674.
Gao, Z-H, et al. “Controlled Release of a Contraceptive Steroid from Biodegradable and Injectable Gel Formulations:In VitroEvaluation”, Pharmaceutical Research, vol. 12, No. 6 (1995) pp. 857-863.
Minto, C., et al. “Pharmacokinetics and Pharmacodynamics of Nandrolone Esters in Oil Vehicle: Effects of Ester, Injection Site and Injection Volume”, Journal of Pharmacology and Experimental Therapeutics, vol. 281, No. 1 (1997) pp. 93-102.
Ostro, M., et al. “Use of Liposomes as Injectable-Drug Delivery Systems”, American Journal of Hospital Pharmacy, vol. 46 (1989) pp. 1576-1587.
Rao, K., “Recent Developments of Collagen-Based Materials for Medical Applications and Drug Delivery Systems”, J. Biomaterial Sci. Polymer, vol. 7, No. 7 (1995) pp. 623-645.
Rohatagi, S., et al. “Pharmacokinetic and Pharmacodynamic Evaluation of Triamcinolone Acetonide After Intravenous, Oral, and Inhaled Administration”, J. Clinical Pharmacology (1995) pp. 1187-1193.
Tjwa, M., “Budesonide Inhaled via Turbuhaler: A More Effective Treatment for Astha Than Beclomethasone Dipropionate via Roahaler”, Annals of Allergy, Asthma, and Immunology, vol. 75 (1995) pp. 107-111.
Wilen, S., et al., “Strategies in Optical Resolutions”, Tetrahedron Report No. 38, vol. 33, pp. 2725-2736.
Chien Shuchean
Novak Gerald
Truyen Luc
Yuen Eric
Anderson James D
Finn Meghan
Janssen Pharmaceutica N.V.
LandOfFree
Methods for QT interval control does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for QT interval control, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for QT interval control will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4232526